title: Management of cutaneous warts: an evidence-based approach.
abstract: Cutaneous warts are benign epidermal proliferations caused by human papillomavirus infection. Treatment aims to cure the patient's physical and psychological discomfort, and to prevent the spread of infection by contact with other body areas or with other individuals. Among the available medical and destructive therapeutic options for cutaneous warts, none is uniformly effective or virucidal. Moreover, in most cases the safety and efficacy of these treatment options has not been assessed in randomized controlled trials, so that the reproducibility of many of the listed treatments is difficult to evaluate and a possible placebo effect cannot be ruled out. This article provides indications for the management of patients with cutaneous warts through an evidence-based approach, considering a first-, second-, and third-line therapy for each clinical form. The first line includes medical treatments useful to cure single, or few, and/or small common warts of short duration (<1 year). If these treatments have failed or are contraindicated, cryotherapy may be considered as second-line therapy. For recurrent or difficult-to-treat lesions, a third-line of therapy includes a variety of alternative therapeutic options that are in clinical use but are not necessarily approved by the US FDA, and their use may be further limited by adverse effects.
authors.affiliation: Dermatology Clinic, University of Catania, Catania, Italy. cldermct@nti.it
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Micali
authors.forename: Federica
authors.initials: F
authors.lastname: Dall'Oglio
authors.forename: Maria R
authors.initials: MR
authors.lastname: Nasca
authors.forename: Aurora
authors.initials: A
authors.lastname: Tedeschi
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D017679:Cryotherapy / Q000379:methods; D003879:Dermatologic Agents / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D005148:Facial Dermatoses / Q000628:therapy; D005533:Foot Dermatoses / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods; D053685:Laser Therapy; D010778:Photochemotherapy / Q000379:methods; D016032:Randomized Controlled Trials as Topic; D020156:Salicylic Acid / Q000627:therapeutic use; D014860:Warts / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*
chemical_list: D000998:Antiviral Agents; D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; D020156:Salicylic Acid